Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical trial assessing ATI-1701

Next Previous
X
Search
Trial Profile

A phase I clinical trial assessing ATI-1701

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATI-1701 (Primary)
  • Indications Tularaemia
  • Focus Adverse reactions

    • Most Recent Events

    • 13 Aug 2024 According to Appili Therapeutics media release, the company expects an IND submission in 2025.
    • 25 Jul 2024 According to Appili Therapeutics media release, ATI-1701 has been awarded a total of US$14 million in U.S. Air Force Academy commitments, facilitating essential activities like manufacturing, non-clinical studies, and regulatory activities for an Investigational New Drug (IND) application.
    • 15 Dec 2023 According to Appili Therapeutics media release, Pre-IND meeting with the FDA granted to discuss regulatory, CMC, toxicology, and Phase 1 strategies of ATI-1701 and expects to receive feedback in early 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top